Trial Profile
A safety and efficacy trial of dalfampridine extended release (Fampridine) in patients with multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Dec 2015 New trial record